The role of chemotherapy in patients with stage IB gastric adenocarcinoma: a real-world competing risk analysis
Abstract Background This study aimed to investigate the potential effect of adjuvant chemotherapy in patients diagnosed with stage IB gastric adenocarcinoma (GAC). Method A total of 1727 patients were included in the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2015 and d...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-04-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12957-022-02591-5 |
| _version_ | 1818480777197780992 |
|---|---|
| author | Yangyang Xie Danwei Du Xue Song Xiaowen Li Zhongkai Ni Hai Huang |
| author_facet | Yangyang Xie Danwei Du Xue Song Xiaowen Li Zhongkai Ni Hai Huang |
| author_sort | Yangyang Xie |
| collection | DOAJ |
| description | Abstract Background This study aimed to investigate the potential effect of adjuvant chemotherapy in patients diagnosed with stage IB gastric adenocarcinoma (GAC). Method A total of 1727 patients were included in the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2015 and divided into the chemotherapy and no-chemotherapy groups. Then, the methods of Kaplan-Meier analysis, propensity score matching (PSM), and competing risk analysis were implemented. Results After PSM, no significant difference was found in the chemotherapy and no-chemotherapy groups in overall survival (OS) (p=0.4) and cancer-specific survival (CSS) (p=0.12) in survival curves. The competing risk analysis presented that the 5-year cumulative incidence of cancer-specific death (CSD) was significantly lower in patients receiving chemotherapy (11.5% vs. 20.8%, p=0.007), while no significant discrepancy was observed in other causes of death (OCD) in both groups (10.6% vs. 10.9%, p=0.474). Multivariable competing risks regression models presented a significant correlation between chemotherapy and CSD (HR, 0.51; 95%CI, 0.31–0.82; p=0.007). Conclusion The stage IB GAC patients can benefit from adjuvant chemotherapy based on this competing risk analysis. |
| first_indexed | 2024-12-10T11:26:51Z |
| format | Article |
| id | doaj.art-9460915bfe3b4d858fbb09438779e21b |
| institution | Directory Open Access Journal |
| issn | 1477-7819 |
| language | English |
| last_indexed | 2024-12-10T11:26:51Z |
| publishDate | 2022-04-01 |
| publisher | BMC |
| record_format | Article |
| series | World Journal of Surgical Oncology |
| spelling | doaj.art-9460915bfe3b4d858fbb09438779e21b2022-12-22T01:50:43ZengBMCWorld Journal of Surgical Oncology1477-78192022-04-0120111110.1186/s12957-022-02591-5The role of chemotherapy in patients with stage IB gastric adenocarcinoma: a real-world competing risk analysisYangyang Xie0Danwei Du1Xue Song2Xiaowen Li3Zhongkai Ni4Hai Huang5Department of General Surgery, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical UniversityDepartment of General Surgery, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical UniversityDepartment of Respiratory and Critical Care Medicine, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical UniversityDepartment of General Surgery, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical UniversityDepartment of General Surgery, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical UniversityDepartment of General Surgery, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical UniversityAbstract Background This study aimed to investigate the potential effect of adjuvant chemotherapy in patients diagnosed with stage IB gastric adenocarcinoma (GAC). Method A total of 1727 patients were included in the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2015 and divided into the chemotherapy and no-chemotherapy groups. Then, the methods of Kaplan-Meier analysis, propensity score matching (PSM), and competing risk analysis were implemented. Results After PSM, no significant difference was found in the chemotherapy and no-chemotherapy groups in overall survival (OS) (p=0.4) and cancer-specific survival (CSS) (p=0.12) in survival curves. The competing risk analysis presented that the 5-year cumulative incidence of cancer-specific death (CSD) was significantly lower in patients receiving chemotherapy (11.5% vs. 20.8%, p=0.007), while no significant discrepancy was observed in other causes of death (OCD) in both groups (10.6% vs. 10.9%, p=0.474). Multivariable competing risks regression models presented a significant correlation between chemotherapy and CSD (HR, 0.51; 95%CI, 0.31–0.82; p=0.007). Conclusion The stage IB GAC patients can benefit from adjuvant chemotherapy based on this competing risk analysis.https://doi.org/10.1186/s12957-022-02591-5Stage IB gastric cancerChemotherapyCompeting risk analysis |
| spellingShingle | Yangyang Xie Danwei Du Xue Song Xiaowen Li Zhongkai Ni Hai Huang The role of chemotherapy in patients with stage IB gastric adenocarcinoma: a real-world competing risk analysis World Journal of Surgical Oncology Stage IB gastric cancer Chemotherapy Competing risk analysis |
| title | The role of chemotherapy in patients with stage IB gastric adenocarcinoma: a real-world competing risk analysis |
| title_full | The role of chemotherapy in patients with stage IB gastric adenocarcinoma: a real-world competing risk analysis |
| title_fullStr | The role of chemotherapy in patients with stage IB gastric adenocarcinoma: a real-world competing risk analysis |
| title_full_unstemmed | The role of chemotherapy in patients with stage IB gastric adenocarcinoma: a real-world competing risk analysis |
| title_short | The role of chemotherapy in patients with stage IB gastric adenocarcinoma: a real-world competing risk analysis |
| title_sort | role of chemotherapy in patients with stage ib gastric adenocarcinoma a real world competing risk analysis |
| topic | Stage IB gastric cancer Chemotherapy Competing risk analysis |
| url | https://doi.org/10.1186/s12957-022-02591-5 |
| work_keys_str_mv | AT yangyangxie theroleofchemotherapyinpatientswithstageibgastricadenocarcinomaarealworldcompetingriskanalysis AT danweidu theroleofchemotherapyinpatientswithstageibgastricadenocarcinomaarealworldcompetingriskanalysis AT xuesong theroleofchemotherapyinpatientswithstageibgastricadenocarcinomaarealworldcompetingriskanalysis AT xiaowenli theroleofchemotherapyinpatientswithstageibgastricadenocarcinomaarealworldcompetingriskanalysis AT zhongkaini theroleofchemotherapyinpatientswithstageibgastricadenocarcinomaarealworldcompetingriskanalysis AT haihuang theroleofchemotherapyinpatientswithstageibgastricadenocarcinomaarealworldcompetingriskanalysis AT yangyangxie roleofchemotherapyinpatientswithstageibgastricadenocarcinomaarealworldcompetingriskanalysis AT danweidu roleofchemotherapyinpatientswithstageibgastricadenocarcinomaarealworldcompetingriskanalysis AT xuesong roleofchemotherapyinpatientswithstageibgastricadenocarcinomaarealworldcompetingriskanalysis AT xiaowenli roleofchemotherapyinpatientswithstageibgastricadenocarcinomaarealworldcompetingriskanalysis AT zhongkaini roleofchemotherapyinpatientswithstageibgastricadenocarcinomaarealworldcompetingriskanalysis AT haihuang roleofchemotherapyinpatientswithstageibgastricadenocarcinomaarealworldcompetingriskanalysis |